BRAIN AG Presents New Strategy at Capital Markets Day
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) has today successfully hosted its second Capital Markets Day (CMD) for analysts and institutional investors at the technology campus in Zwingenberg, Germany. BRAIN´s management there communicated the strategy on the basis of which the biotech company intends to continue its successful growth path.
The event was also webcasted to allow a maximum attendance in times of the Corona pandemic. Around 60% of the BRAIN AG shareholder capital has participated in the event.
Strategic Targets and Focused New Business Development Pipeline Presented
BRAIN AG management presented the strategic pillars for its future success. The company will emphasize the growth of its products-based business, maintain its strong research foundation and remain a strong development partner for industrial biotechnology through its tailor made solutions (TMS). With the transformation of the products-based business from a purchase for resale model to own production and fermentation BRAIN management believes it can create significant value upside. Selective M&A might accelerate these strategic targets. In this way BRAIN aims to continue its successful growth path.
In addition, a focused new business development pipeline was presented. BRAIN AG will focus its scientific and financial resources on the most promising projects with the aim to meet customer needs, shorten the time to market and optimize the value. These projects address the big societal topics of nutrition, health and the environment.
Adriaan Moelker, CEO BRAIN AG, states: "My management team and I were very pleased by the strong attendance at our CMD and the intensive dialogue with our shareholders. We have now clearly set and communicated a mid-term corporate strategy. Brain AG will significantly grow its products-based business while remaining committed to developing breakthrough solutions based on our deep scientific foundation.“
New Mid-Term Targets Announced
BRAIN AG has also communictated new mid-term targets. The company plans to double revenues from the base in fiscal year ‘18/’19 and achieve an EBITDA margin of 15% (+/-5%) over the next four to five years. In addition, BRAIN aims to achieve a proportion of new product sales around 30% of total revenues.
Lukas Linnig, BRAIN´s new CFO from Oct. 1st, says: "It is very important for us to keep our shareholders on top of recent developments and our next strategic steps. Our mid-term targets are ambitious but fully backed by our development plan.”
All presentation material is available in the investor relations section of the BRAIN website.
Press Image
About BRAIN
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.